Disc Medicine: prices 6,000,000-share offering at $75.00

What happened

• On Oct 20, 2026, Disc Medicine entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the underwriters, for an underwritten public offering of 6,000,000 shares of common stock at a price to the public of $75.00 per share.
• The company granted the underwriters an option exercisable for 30 days to purchase up to an additional 900,000 shares at the public offering price less underwriting discounts and commissions. All of the 6,000,000 firm shares were sold by the company and the offering closed on Oct 22, 2026.
• The company reported that the net proceeds from the offering are expected to be approximately $422,400,000, or approximately $485,900,000 if the underwriters exercise their option in full.
• On Oct 20, 2026, the company announced that its preliminary unaudited cash, cash equivalents and marketable securities as of Sep 30, 2026 were approximately $682,800,000. The company also announced that it expects that its cash, cash equivalents and marketable securities, together with the estimated net proceeds from the offering, will be sufficient to fund its current operating and capital expenditure plans and its debt service obligations into 2030, without taking into account any potential net cash inflows from bitopertin or any other marketed product.

Key details

• Offering size: 6,000,000 firm shares at $75.00 per share; option for 900,000 additional shares for 30 days.
• Estimated net proceeds: approximately $422,400,000 without option; approximately $485,900,000 with full exercise.
• Preliminary cash position: approximately $682,800,000 as of Sep 30, 2026 (unaudited, preliminary and subject to change).
• Underwriting representatives: Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co.; offering made under the company’s Form S-3 shelf registration.

Why it may matter

• Item 1.01: entry into a material definitive agreement (the underwriting agreement) covering the offering.
• Item 2.02: results of operations and financial condition (preliminary cash, cash equivalents and marketable securities as of Sep 30, 2026).
• Item 8.01: other events (press releases announcing the commencement and pricing of the offering and a cautionary statement regarding forward-looking statements).
• The filing does not show why the insider traded or why the company acted.